Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

346 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation.
Chapman RW, Minnicozzi M, Celly CS, Phillips JE, Kung TT, Hipkin RW, Fan X, Rindgen D, Deno G, Bond R, Gonsiorek W, Billah MM, Fine JS, Hey JA. Chapman RW, et al. Among authors: billah mm. J Pharmacol Exp Ther. 2007 Aug;322(2):486-93. doi: 10.1124/jpet.106.119040. Epub 2007 May 11. J Pharmacol Exp Ther. 2007. PMID: 17496165
SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist.
Anthes JC, Chapman RW, Richard C, Eckel S, Corboz M, Hey JA, Fernandez X, Greenfeder S, McLeod R, Sehring S, Rizzo C, Crawley Y, Shih NY, Piwinski J, Reichard G, Ting P, Carruthers N, Cuss FM, Billah M, Kreutner W, Egan RW. Anthes JC, et al. Among authors: billah m. Eur J Pharmacol. 2002 Aug 23;450(2):191-202. doi: 10.1016/s0014-2999(02)02124-6. Eur J Pharmacol. 2002. PMID: 12206858
Pharmacology of N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitor.
Billah MM, Cooper N, Minnicozzi M, Warneck J, Wang P, Hey JA, Kreutner W, Rizzo CA, Smith SR, Young S, Chapman RW, Dyke H, Shih NY, Piwinski JJ, Cuss FM, Montana J, Ganguly AK, Egan RW. Billah MM, et al. J Pharmacol Exp Ther. 2002 Jul;302(1):127-37. doi: 10.1124/jpet.302.1.127. J Pharmacol Exp Ther. 2002. PMID: 12065709 Clinical Trial.
346 results